Tuberc Respir Dis.  2016 Apr;79(2):70-73. 10.4046/trd.2016.79.2.70.

The 2009 H1N1 Pandemic Influenza in Korea

• Kim JY

• KMID: 2320768
• DOI: http://doi.org/10.4046/trd.2016.79.2.70

Abstract

In late March of 2009, an outbreak of influenza in Mexico, was eventually identified as H1N1 influenza A. In June 2009, the World Health Organization raised a pandemic alert to the highest level. More than 214 countries have reported confirmed cases of pandemic H1N1 influenza A. In Korea, the first case of pandemic influenza A/H1N1 infection was reported on May 2, 2009. Between May 2009 and August 2010, 750,000 cases of pandemic influenza A/H1N1 were confirmed by laboratory test. The H1N1-related death toll was estimated to reach 252 individuals. Almost one billion cases of influenza occurs globally every year, resulting in 300,000 to 500,000 deaths. Influenza vaccination induces virus-neutralizing antibodies, mainly against hemagglutinin, which provide protection from invading virus. New quadrivalent inactivated influenza vaccine generates similar immune responses against the three influenza strains contained in two types of trivalent vaccines and superior responses against the additional B strain.

Keyword

Influenza; Pandemic; Vaccines

MeSH Terms

Antibodies
Hemagglutinins
Influenza Vaccines
Influenza, Human*
Korea*
Mexico
Pandemics*
Vaccination
Vaccines
World Health Organization
Antibodies
Hemagglutinins
Influenza Vaccines
Vaccines

Figure

• 

  Figure 1 Peak month of flu activity from 1982–1983 through 2013–2014 in the United States. Adopted from Centers for Disease Control and Prevention, according to Creative Commons Licenses20.

Reference

1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002; 76:105–115.

2. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis. 2007; 195:1018–1028.

3. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science. 1997; 275:1793–1796.

4. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005; 310:77–80.

5. Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010; 84:1715–1721.

6. Masurel N, Marine WM. Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man. Am J Epidemiol. 1973; 97:44–49.

7. World Health Organization. Pandemic (H1N1) 2009: update 112 [Internet]. Geneva: World Health Organization;2010. cited 2010 Oct 4. http://www.who.int/csr/don/2010_08_06/en/index.html.

8. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009; 360:2605–2615.

9. Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis. 2011; 52:Suppl 1. S75–S82.

10. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012; 12:687–695.

11. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med. 2013; 10:e1001558.

12. Fowlkes AL, Arguin P, Biggerstaff MS, Gindler J, Blau D, Jain S, et al. Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin Infect Dis. 2011; 52:Suppl 1. S60–S68.

13. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009; 302:1896–1902.

14. Suh M, Kang DR, Lee DH, Choi YJ, Tchoe B, Nam CM, et al. Socioeconomic burden of influenza in the Republic of Korea,2007-2010. PLoS One. 2013; 8:e84121.

15. Choi WI, Yim JJ, Park J, Kim SC, Na MJ, Lee WY, et al. Clinical characteristics and outcomes of H1N1-associated pneumonia among adults in South Korea. Int J Tuberc Lung Dis. 2011; 15:270–275.

16. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009; 361:1935–1944.

17. ANZIC Influenza Investigators. Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009; 361:1925–1934.

18. Lee MC, Kim HY, Kong SG, Kim YM, Park SE, Im YT, et al. Clinical characteristics of pandemic influenza A (H1N1) 2009 pediatric infection in Busan and Gyeongsangnam-do: one institution. Tuberc Respir Dis. 2012; 72:493–500.

19. Kim YW, Yoon SJ, Oh IH. The economic burden of the 2009 pandemic H1N1 influenza in Korea. Scand J Infect Dis. 2013; 45:390–396.

20. Centers for Disease Control and Prevention. The flu season [Internet]. Atlanta: Centers for Disease Control and Prevention;2014. cited 2015 Dec 11. http://www.cdc.gov/flu/about/season/flu-season.htm.

21. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289:179–186.

22. Webster RG, Wright SM, Castrucci MR, Bean WJ, Kawaoka Y. Influenza: a model of an emerging virus disease. Intervirology. 1993; 35:16–25.

23. Webster RG, Kendal AP, Gerhard W. Analysis of antigenic drift in recently isolated influenza A (H1N1) viruses using monoclonal antibody preparations. Virology. 1979; 96:258–264.

24. Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses. 2015; 9:Suppl 1. 3–12.

25. Uyeki TM. Preventing and controlling influenza with available interventions. N Engl J Med. 2014; 370:789–791.

26. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis. 2014; 59:1519–1524.

27. Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013; 207:1878–1887.

28. Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewe W, et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine. 2014; 32:1480–1487.

29. Centers for Disease Control and Prevention. Vaccination: who should do it, who should not and who should take precautions [Internet]. Atlanta: Centers for Disease Control and Prevention;2015. cited 2015 Dec 11. http://www.cdc.gov/flu/protect/whoshouldvax.htm.